Search

Displaying results 1801 - 1810 of 6951 in total
  1. Drug

    Amorolfine

    go.drugbank.com/drugs/DB09056
    ApprovedWithdrawn

    It is not approved for the treatment of onychomycosis in the United States or Canada. … It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  2. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    [L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.

  4. Drug

    Glutamic acid

    go.drugbank.com/drugs/DB00142
    ApprovedInvestigationalNutraceutical

    A peptide that is a homopolymer of glutamic acid.

    Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSION
  5. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells.

  7. Drug

    Streptococcus pneumoniae type 18c capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10335
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For Injection
  8. Drug

    Fluocinolone acetonide

    go.drugbank.com/drugs/DB00591
    ApprovedInvestigationalVet approved

    [T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices.

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Corticosteroid Hormone Receptor Agonists
  9. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  10. Drug

    Sulfathiazole

    go.drugbank.com/drugs/DB06147
    ApprovedVet approvedWithdrawn

    Except for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.[L43942]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use